Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial

L. Pavlu, M. Vicha, J. Flasik, J. Petrkova, M. Taborsky, T. Kacirkova, O. Holy

. 2024 ; 168 (3) : 229-234. [pub] 20230206

Language English Country Czech Republic

Document type Journal Article, Comparative Study, Multicenter Study, Randomized Controlled Trial

BACKGROUND AND AIMS: There are limited data on real clinical practice in heart failure patients in the Czech Republic. We analysed the clinical parameters from the Moravian Midlands Registry (MMR) and compared them to LCZ696 patients in the Paradigm-HF trial. The Moravian Midlands Registry is a retrospective patient database from two outpatient cardiology centres in the Czech Republic. The Paradigm-HF is a large-scale prospective randomized multicentre trial with more than 8000 individuals with stabilized chronic heart failure. METHODS: A retrospective analysis of heart failure with reduced ejection fraction patients from two outpatient cardiology centres in the Czech Republic from October 2016 to December 2019. RESULTS: Patients in the MMR were younger (60.5 ± 10.7 vs 63.8 ± 11.5 years, P<0.05), had a higher body mass index (30.3 ± 5.0 vs 28.1 ± 5.5, P<0.05) and higher serum creatinine level (101.9 ± 36.0 vs 99.9 ± 26.5 μmol/L, P<0.05). MMR patients had lower left ventricular ejection fraction (27.8 ± 6.9 vs 29.6 ± 6.1%, P<0.05). The serum N-terminal pro-B-type natriuretic peptide, [2563.5 (377-3536) vs 1631 (885-3154), was non significantly higher P=0.07]. Pharmacotherapy use differed for mineralocorticoid antagonist (91.4% in MMR vs 54.2% in Paradigm-HF), and digoxin (13.5% vs 29.2%). Beta-blocker use was similar (96.2% vs 93.1%) as was angiotensin-converting enzyme (ACE) inhibitors - (71.2% vs 78.0%) and angiotensin-receptor blockers - ARB (27.9% vs 22.2%). Dosages of the commonly used ACE inhibitors at the screening visit (Paradigm-HF) / before angiotensin receptor-neprilysin inhibitor administration (MMR) differed significantly only for ramipril (7.0 ± 3.1 mg vs 4.8 ± 2.9 mg, P<0.05), dosages of ARB were - losartan (67.1 ± 30.2 vs 39.6 ± 32.0 mg, P=0.09) and valsartan (181.5 ± 71.1 vs 130.9 ± 82.2 mg, P=0.07). There was a substantial difference in device-based therapy (ICD in 60.6%, CRT 25.9% in MMR vs 14.9% and 7.0% in Paradigm-HF). CONCLUSION: The differences between the groups for the majority of clinical parameters compared were minimal, except for younger age, higher body mass index and serum creatinine level and lower left ventricular ejection fraction and substantially lower dosage of administered ramipril prior to commencing sacubitril/valsartan therapy. There was a higher prevalence of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT) in the MMR group.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24017565
003      
CZ-PrNML
005      
20250527095255.0
007      
ta
008      
241004s2024 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.006 $2 doi
035    __
$a (PubMed)36748670
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Pavlů, Luděk $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0236019
245    12
$a A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial / $c L. Pavlu, M. Vicha, J. Flasik, J. Petrkova, M. Taborsky, T. Kacirkova, O. Holy
520    9_
$a BACKGROUND AND AIMS: There are limited data on real clinical practice in heart failure patients in the Czech Republic. We analysed the clinical parameters from the Moravian Midlands Registry (MMR) and compared them to LCZ696 patients in the Paradigm-HF trial. The Moravian Midlands Registry is a retrospective patient database from two outpatient cardiology centres in the Czech Republic. The Paradigm-HF is a large-scale prospective randomized multicentre trial with more than 8000 individuals with stabilized chronic heart failure. METHODS: A retrospective analysis of heart failure with reduced ejection fraction patients from two outpatient cardiology centres in the Czech Republic from October 2016 to December 2019. RESULTS: Patients in the MMR were younger (60.5 ± 10.7 vs 63.8 ± 11.5 years, P<0.05), had a higher body mass index (30.3 ± 5.0 vs 28.1 ± 5.5, P<0.05) and higher serum creatinine level (101.9 ± 36.0 vs 99.9 ± 26.5 μmol/L, P<0.05). MMR patients had lower left ventricular ejection fraction (27.8 ± 6.9 vs 29.6 ± 6.1%, P<0.05). The serum N-terminal pro-B-type natriuretic peptide, [2563.5 (377-3536) vs 1631 (885-3154), was non significantly higher P=0.07]. Pharmacotherapy use differed for mineralocorticoid antagonist (91.4% in MMR vs 54.2% in Paradigm-HF), and digoxin (13.5% vs 29.2%). Beta-blocker use was similar (96.2% vs 93.1%) as was angiotensin-converting enzyme (ACE) inhibitors - (71.2% vs 78.0%) and angiotensin-receptor blockers - ARB (27.9% vs 22.2%). Dosages of the commonly used ACE inhibitors at the screening visit (Paradigm-HF) / before angiotensin receptor-neprilysin inhibitor administration (MMR) differed significantly only for ramipril (7.0 ± 3.1 mg vs 4.8 ± 2.9 mg, P<0.05), dosages of ARB were - losartan (67.1 ± 30.2 vs 39.6 ± 32.0 mg, P=0.09) and valsartan (181.5 ± 71.1 vs 130.9 ± 82.2 mg, P=0.07). There was a substantial difference in device-based therapy (ICD in 60.6%, CRT 25.9% in MMR vs 14.9% and 7.0% in Paradigm-HF). CONCLUSION: The differences between the groups for the majority of clinical parameters compared were minimal, except for younger age, higher body mass index and serum creatinine level and lower left ventricular ejection fraction and substantially lower dosage of administered ramipril prior to commencing sacubitril/valsartan therapy. There was a higher prevalence of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT) in the MMR group.
650    _2
$a lidé $7 D006801
650    12
$a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a valsartan $x terapeutické užití $7 D000068756
650    12
$a tepový objem $x fyziologie $7 D013318
650    12
$a registrace $7 D012042
650    12
$a bifenylové sloučeniny $x terapeutické užití $7 D001713
650    12
$a aminobutyráty $x terapeutické užití $7 D000613
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    12
$a fixní kombinace léků $7 D004338
650    12
$a antagonisté receptorů pro angiotenzin $x terapeutické užití $7 D057911
650    _2
$a tetrazoly $x terapeutické užití $7 D013777
650    _2
$a natriuretický peptid typu B $x krev $7 D020097
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Vícha, Marek $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0229304
700    1_
$a Flašík, Jakub $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0271081
700    1_
$a Petřková, Jana $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0117676
700    1_
$a Táborský, Miloš, $d 1962- $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 jn20010310074
700    1_
$a Schovánková, Tereza $u Science and Research Centre, Faculty of Health Sciences, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0331955
700    1_
$a Holý, Ondřej $u Science and Research Centre, Faculty of Health Sciences, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0222173
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 3 (2024), s. 229-234
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36748670 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20241004 $b ABA008
991    __
$a 20250527095255 $b ABA008
999    __
$a ok $b bmc $g 2316485 $s 1229515
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 168 $c 3 $d 229-234 $e 20230206 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK124 $a Pubmed-20241004

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...